NuoHui Venture Fund
诺辉创投基金
NuoHui Venture Fund (诺辉创投基金) is a venture capital fund that appears in elsewhere's corpus as a co-investor in biotech deals, though the bundle contains no dedicated profile of the fund itself. Per 5Y Capital's reporting, it participated in Mirxes's $87 million Series C in 2021 as a follow-on investor alongside lead China Resources Zhengda Life Science Fund and others including Rock Springs Capital and EDBI , and again in Mirxes's $50 million Series D in 2023 alongside EDBI, A*STAR, and Mitsui & Co. . elsewhere's corpus does not cover the fund's founding date, size, strategy, or team in any depth.
AI-generated — may contain errors, please verify.
Coverage
I'm Zhilin Yang of Moonshot AI, and I'm here for Alibaba Cloud.
This endorsement is a little too salty.
Mirxes Completes $50 Million Series D to Accelerate Cancer Early-Screening Pipeline R&D and Commercialization
Focused on innovative blood-based early screening products and services for cancer.
Gaorong Monthly · October | Gaorong Ventures Named Among Zero2IPO's Top 10 VC Firms of the Year; Nuro Closes Major Series D Round
Autonomous driving, healthcare, and chip sectors see new funding rounds; Genki Forest unveils "Triple Zero Factory" strategy; Dingdong Maicai stabilizes prices and ensures supply.
Mirxes Completes $87 Million Series C Round to Develop Early Cancer Screening Products Based on Leading miRNA Technology
Focused on microRNA technology, dedicated to early disease diagnosis.
